Investors bet $195 million on Cambridge University research

2 April 2019
universityofcambridge-big

UK-based investment firm Cambridge Innovation Capital (CIC) has raised £150 million ($195 million) for investment in life science businesses in the Cambridge area.

The firm focuses on investing in technologies which stem from research at Cambridge University, one of the world’s leading academic centers. CIC has now raised a total of £275 million for this purpose.

The financing was supported by a range of new and existing investors, with the University of Cambridge and Cambridge University Endowment Fund making the cornerstone investment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical